The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| PLX | +83.08% | -26.32% | -5.92% | -99% |
| S&P | +17.53% | +93.66% | +14.13% | +380% |
Protalix Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development, production, and commercialization of recombinant therapeutic proteins based on plant cell based expression system. Its products include Alidornase alfa, PRX-115 and PRX-11. The company was by Yoseph Shaaltiel in 1993 and is headquartered in Carmiel, Israel.
Investors did not like the company's latest regulatory update.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $15.66M | 16.2% |
| Gross Profit | $9.79M | 143.6% |
| Gross Margin | 62.51% | 32.7% |
| Market Cap | $117.82M | 37.3% |
| Market Cap / Employee | $0.55M | 0.0% |
| Employees | 213 | 2.4% |
| Net Income | $0.16M | 107.4% |
| EBITDA | $1.53M | 172.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $17.90M | -23.5% |
| Accounts Receivable | $9.44M | -6.7% |
| Inventory | 21.1 | 2.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $3.88M | -9.5% |
| Short Term Debt | $1.47M | -93.3% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 7.38% | 23.7% |
| Return On Invested Capital | -23.41% | -23.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$5.66M | -49.8% |
| Operating Free Cash Flow | -$5.23M | -45.0% |
| Metric | Q1 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 56.00 | 71.48 | 60.95 | 20.00 | -65.28% |
| Price to Book | 2.62 | 4.27 | 4.49 | 2.56 | -10.86% |
| Price to Sales | 1.81 | 2.67 | 3.28 | 1.94 | -13.86% |
| Price to Tangible Book Value | 2.62 | 4.27 | 4.49 | 2.56 | -10.86% |
| Price to Free Cash Flow TTM | 21.06 | 11.55 | 19.29 | - | |
| Enterprise Value to EBITDA | 14.15 | 15.02 | -43.86 | 60.20 | -289.72% |
| Free Cash Flow Yield | 4.7% | 8.7% | 5.2% | - | |
| Return on Equity | -27.2% | 7.6% | 10.4% | 16.0% | -136.77% |
| Total Debt | $5.68M | $5.53M | $5.24M | $5.35M | -79.55% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
